Real-world experience of bamlanivimab for coronavirus disease 2019 (COVID-19): a case-control study
RN Kumar, EL Wu, V Stosor, WJ Moore… - Clinical Infectious …, 2022 - academic.oup.com
Clinical Infectious Diseases, 2022•academic.oup.com
Abstract Background Coronavirus disease 2019 (COVID-19) has strained healthcare
systems with patient hospitalizations and deaths. Anti-spike monoclonal antibodies,
including bamlanivimab, have demonstrated reduction in hospitalization rates in clinical
trials, yet real-world evidence is lacking. Methods We conducted a retrospective case-control
study across a single healthcare system of nonhospitalized patients, age 18 years or older,
with documented positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
systems with patient hospitalizations and deaths. Anti-spike monoclonal antibodies,
including bamlanivimab, have demonstrated reduction in hospitalization rates in clinical
trials, yet real-world evidence is lacking. Methods We conducted a retrospective case-control
study across a single healthcare system of nonhospitalized patients, age 18 years or older,
with documented positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
Background
Coronavirus disease 2019 (COVID-19) has strained healthcare systems with patient hospitalizations and deaths. Anti-spike monoclonal antibodies, including bamlanivimab, have demonstrated reduction in hospitalization rates in clinical trials, yet real-world evidence is lacking.
Methods
We conducted a retrospective case-control study across a single healthcare system of nonhospitalized patients, age 18 years or older, with documented positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing, risk factors for severe COVID-19, and referrals for bamlanivimab via emergency use authorization. Cases were defined as patients who received bamlanivimab; contemporary controls had a referral order placed but did not receive bamlanivimab. The primary outcome was 30-day hospitalization rate from initial positive SARS-CoV-2 polymerase chain reaction (PCR). Descriptive statistics, including χ 2 and Mann-Whitney U test, were performed. Multivariable logistic regression was used for adjusted analysis to evaluate independent associations with 30-day hospitalization.
Results
Between 30 November 2020 and 19 January 2021, 218 patients received bamlanivimab (cases), and 185 were referred but did not receive drug (controls). Thirty-day hospitalization rate was significantly lower among patients who received bamlanivimab (7.3% vs 20.0%, risk ratio [RR] 0.37, 95% confidence interval [CI]: .21–.64, P < .001), and the number needed to treat was 8. On logistic regression, odds of hospitalization were increased in patients not receiving bamlanivimab and with a higher number of pre-specified comorbidities (odds ratio [OR] 4.19 ,95% CI: 1.31–2.16, P < .001; OR 1.68, 95% CI: 2.12–8.30, P < .001, respectively).
Conclusions
Ambulatory patients with COVID-19 who received bamlanivimab had a lower 30-day hospitalization than control patients in real-world experience. We identified receipt of bamlanivimab and fewer comorbidities as protective factors against hospitalization.
Bamlanivimab’s role in preventing hospitalization associated with coronavirus disease 2019 (COVID-19) remains unclear. In a real-world, retrospective study of 403 high-risk, ambulatory patients with COVID-19, receipt of bamlanivimab compared to no monoclonal antibody therapy was associated with lower 30-day hospitalization.
Oxford University Press